Effect of dexmedetomidine on endothelial glycocalyx in patients undergoing cardiac valve replacement under cardiopulmonary bypass

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200064164

Enrollment

Unknown

Registered

2022-09-28

Start date

2022-09-29

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart valve replacement operation

Interventions

group D:Dextrmedetomidine injection

group C:0.9% normal saline injection

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. From September 2022 to December 2022, 64 patients were selected for cardiac valve replacement under CPB in the Affiliated Hospital of North Sichuan Medical College; 2. Aged 18-65 years; 3. ASA grade II-III; 4. Heart function NYHA grade II-III.

Exclusion criteria

Exclusion criteria: 1. Those who are allergic to dexmedetomidine and all drugs used in this trial; 2. Sinus bradycardia ( 30 kg/m2.

Design outcomes

Primary

Measure	Time frame
heparan sulfate;syndecan-1;	—

Secondary

Measure	Time frame
Tumor necrosis factor-a;Interleukin 6;Serum creatinine;Serum urea;Blood neutrophil and monocyte count;prothrombin time;Type and quantity of intraoperative blood transfusion products and intraoperative blood loss;Times of hypotension (mean arterial pressure<55 mmHg) and heart rate<60 beats/min before cardiopulmonary bypass and after cardiac rebound;General information (height, ASA grade and type of surgery, etc.);Time (cardiopulmonary bypass, extubation time and stay time in the intensive care unit);Drainage volume in the first three days after operation;Dosage of dexmedetomidine, atropine and vasoactive drugs;	—

Measure

Time frame

Tumor necrosis factor-a;Interleukin 6;Serum creatinine;Serum urea;Blood neutrophil and monocyte count;prothrombin time;Type and quantity of intraoperative blood transfusion products and intraoperative blood loss;Times of hypotension (mean arterial pressure<55 mmHg) and heart rate<60 beats/min before cardiopulmonary bypass and after cardiac rebound;General information (height, ASA grade and type of surgery, etc.);Time (cardiopulmonary bypass, extubation time and stay time in the intensive care unit);Drainage volume in the first three days after operation;Dosage of dexmedetomidine, atropine and vasoactive drugs;

—

Countries

China

Contacts

Public ContactFangjun Wang

Affiliated Hospital of North Sichuan Medical College

wfjlxy006@126.com+86 13458253172

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026